Gestational diabetes needs to be managed

H David McIntyre and Jeremy J N Oats
Med J Aust 2013; 198 (11): . || doi: 10.5694/mja13.10421
Published online: 17 June 2013

In reply: Taylor welcomes a strong evidence base for clinical practice, which is echoed by d’Emden and colleagues. However, their strong support for the current Australian diagnostic criteria for gestational diabetes mellitus (GDM) is surprising, given that these criteria are the product of an “Ad Hoc Working Party” report.1 This guideline, published in 1991, clearly acknowledged a lack of strong evidence and advocated criteria that were based on best available rounded values for the 95th centile of venous plasma glucose (VPG) levels in the fasting state (5.5 mmol/L) and 2 hours after a 75 g glucose load (8.0 mmol/L) — values that had been published in an unreferenced overview of Australian and European data.1 It advocated future prospective studies, such as those which form the basis of the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations.2 Contrary to d’Emden et al’s assertions, the 1991 fasting and 2-hour VPG level cut-offs are misaligned. Contemporary data from the 2120 Australian women in the Hyperglycemia and Adverse Pregnancy Outcome study, using the 75 g oral glucose tolerance test, show that 5.5 mmol/L lies at the 98th centile for fasting VPG level, while 8.0 mmol/L corresponds to the 91st centile for 2-hour VPG level (own unpublished data). A recent summary of ambulatory blood glucose monitoring in pregnancy suggested even tighter normative values, with the 97th centiles for fasting blood glucose level (BGL) (4.8 mmol/L) and 2-hour post-meal BGL (6.6 mmol/L) being lower than previous guesstimates.3

  • H David McIntyre1,2
  • Jeremy J N Oats3

  • 1 Mater Health Services, Brisbane, QLD.
  • 2 University of Queensland, Brisbane, QLD.
  • 3 Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC.


Competing interests:

David McIntyre has received research funding from Novo Nordisk, the National Health and Medical Research Council and the Canadian Institutes of Health Research, and travel assistance and payment for presentations from Novo Nordisk, Sanofi-Aventis, Servier, Sonic Healthcare, AstraZeneca and the Australian Diabetes Educators Association.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.